04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
12:49 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

Rimiducid: Ph I BP-012 started

Bellicum began the open-label, U.S. Phase I BP-012 trial to evaluate BPX-601 plus rimiducid in up to 30 patients. Bellicum has rights to rimiducid from Ariad Pharmaceuticals Inc. under an amended 2006 deal (see BioCentury,...
12:49 , Mar 9, 2017 |  BC Week In Review  |  Clinical News

BPX-601: Ph I BP-012 started

Bellicum began the open-label, U.S. Phase I BP-012 trial to evaluate BPX-601 plus rimiducid (AP1903) in up to 30 patients. Bellicum has rights to rimiducid from Ariad Pharmaceuticals Inc. under an amended 2006 deal (see...
03:48 , Dec 10, 2016 |  BioCentury  |  Product Development

Rules of the road

Investigators and companies have long been devising strategies to mitigate or preempt toxicities from CAR T cell therapies without compromising efficacy. Now, data presented at the American Society of Hematology meeting suggest strategies to prevent...
21:56 , Dec 2, 2016 |  BioCentury  |  Product Development

CNS CAR crash?

Juno Therapeutics Inc. and other investigators in the CAR T field don’t know what caused fatal neurotoxicity in the Phase II ROCKET trial of CAR therapy JCAR015 . But it appears the study’s CNS disease...
07:00 , Jul 18, 2016 |  BioCentury  |  Product Development

ROCKET resumes

The swift release of a clinical hold on Juno Therapeutics Inc .'s ROCKET trial notwithstanding, why and how high-dose fludarabine contributed to fatal neurotoxicity remains an unanswered - and important - question for the CAR...